NR1H2 and myeloid sarcoma: This prompted the development of a new generation of selective agonists, including selective LXRβ-agonists, tissue-selective agonists or agonists targeting the trans-repression/anti-inflammatory actions of LXRs (109) although, to our knowledge, none of these have been tested in preclinical models of MS (Table 1).